Compare State Street SPDR S&P Biotech ETF (XBI) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs DENTSPLY SIRONA Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.18, while DENTSPLY SIRONA Inc trades at $11.38 (market cap $2.31B). The key difference: DENTSPLY SIRONA Inc pays a 5.04% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, DENTSPLY SIRONA Inc nearer its low. Which is the better fit depends on your goals.
| XBI | XRAY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $164.28 | $14.68 |
52-Week Low | $86.92 | $9.64 |
Market Cap | — | $2.31B |
Enterprise Value | — | $4.39B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
DENTSPLY SIRONA (XRAY) trades at $11.40, down 2.23% amid ongoing revenue declines and negative profitability. The stock shows bearish technical signals with support at $11 and resistance at $12. Recent Q2 2026 earnings beat expectations with $0.52 EPS but revenue fell 4.1% year-over-year to $898 million, reflecting persistent challenges in dental markets. The company maintains a 'Hold' analyst consensus with a $11.50 price target while executing its turnaround strategy.
Investment outlook remains cautious given six consecutive quarters of revenue declines and negative net margins. The company's restructuring efforts and new CFO appointment offer potential for operational improvement, but weak European demand and competitive pressures pose significant headwinds. With debt-to-asset ratio rising to 42.88% in 2025, financial leverage adds risk to the recovery thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
